US FDA approves vaccine protecting against six diseases

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/AlekZotoff)
(Image: Getty/AlekZotoff)
Sanofi and MSD received approval for a vaccine that protects children against diseases caused by six infectious agents.

The US Food and Drug Administration (FDA) approved Vaxelis for the prevention of diphtheria, tetanus and pertussis, poliomyelitis, hepatitis B, and diseases due to Haemophilus influenzae type b (Hib), in children.

Vaxelis, an immunization, was developed through a partnership between Sanofi and Merck, known as MSD outside of North America. The companies are currently working to establish a sustainable supply to meet the anticipated US demand, which will not be available until 2020.

A spokesperson for Sanofi told us that the vaccine will be manufactured at Sanofi’s Toronto facility. The spokesperson was not able to disclose the estimated demand, supply needs, or commercialization details at this time.

Combination vaccines and inoculations

Combination vaccines are not uncommon for childhood immunizations: Pediarix, ProQuad, Kinrix, and Pentacel, all combine prevention against diseases. Vaxelis includes most childhood immunization and inoculations apart from Measles, mumps, and Rubella (MMR),pnuemococcal, rotavirus, or varicella vaccines.  

According to an article​ published by the Center for Disease Control (CDC), combined vaccinations lead to higher rates of compliance with vaccination schedules and better protection against disease, as well as decreasing the amount of storage space needed.

Vaxelis includes protection against diseases caused by exposure to Hib bacterium. The Hib vaccine protects against diseases that may develop after exposure to the bacterium such as pneumonia and acute bacterial meningitis.

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us


View more